Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide

NCT06865547 is registered in ClinicalTrials.gov with Yonghong Li as lead sponsor.

NCT NCT06865547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06865547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide
Lead sponsor
Yonghong Li
Phase
Observational
Overall status
Active, not recruiting
Start date
January 22, 2025
Completion date
January 30, 2027
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (adenocarcinoma)